Ze-gen, Inc.

Ze-gen, Inc named a Global Cleantech 100 Clean Technology Company

Ze-gen, Inc named a Global Cleantech 100 Clean Technology Company

September 16, 2009

Recognized by the Guardian and Cleantech Group for potential and likelihood to achieve high growth and high market impact

Boston, MA — September 16, 2009 — Ze-gen, Inc., a clean energy company developing advanced gasification technology to convert waste streams into synthesis gas, today announced it has been named a Global Cleantech 100 company by Guardian News and Media and Cleantech Group™, LLC, providers of leading research, events and advisory services for the cleantech ecosystem.

Pervasis Therapeutics, Inc.

Pervasis Therapeutics Announces $17 Million in Financing and New Board Member

Pervasis Therapeutics Announces $17 Million in Financing and New Board Member

September 16, 2009

Proceeds to Advance Ongoing Clinical Development Programs, Including PVS-10200 for the Treatment of Peripheral Arterial Disease

Yoram Richter, PhD., Joins Company's Board of Directors and Brings Significant Experience in the Cardiovascular Field

Joule Unlimited, Inc.

Joule Biotechnologies Elects Graham Allison to Board of Directors

Joule Biotechnologies Elects Graham Allison to Board of Directors

September 21, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Joule Biotechnologies, Inc., an innovative bioengineering startup developing game-changing alternative energy solutions, today announced the election of Graham Allison to its board of directors.

VisEn Medical, Inc.

VisEn Launches Reninsense680 FAST Molecular Imaging Agent to Enable in vivo Imaging Readouts of Key Biomarkers in Hypertension and Renal Function

VisEn Launches Reninsense680 FAST Molecular Imaging Agent to Enable in vivo Imaging Readouts of Key Biomarkers in Hypertension and Renal Function

September 23, 2009

Data Presented at World Molecular Imaging Congress in Montreal

VisEn Medical, Inc.

VisEn Medical Extends Fluorescence Molecular Tomography (FMT™) Product Line

VisEn Medical Extends Fluorescence Molecular Tomography (FMT™) Product Line

September 23, 2009

New FMT 1500™ and FMT 2500™ LX Models Launched to Meet Global Demand for FMT-enabled True Quantification in Fluorescence in vivo Imaging

LS9

LS9 Secures $25 Million in Latest Round of Funding

LS9 Secures $25 Million in Latest Round of Funding

September 24, 2009

SOUTH SAN FRANCISCO, CA - September 24, 2009 - LS9, the Renewable Petroleum Company™, today announced it successfully completed a $25 million round of funding. Participating investors included CTTV Investments LLC, the venture capital arm of Chevron Technology Ventures LLC; Flagship Ventures; Khosla Ventures and Lightspeed Venture Partners.

Helicos BioSciences Corporation

Helicos Announces System Sale to Correlagen Diagnostics

Helicos Announces System Sale to Correlagen Diagnostics

September 28, 2009

Purchase of a Helicos® Genetic Analysis System includes collaboration on the development of targeted resequencing assays

CAMBRIDGE, Mass., Sep 28, 2009 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS) today announced the sale of a system and a scientific collaboration with Correlagen Diagnostics Inc., a leading provider of genetic tests for disease diagnosis.

Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates

Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates

October 6, 2009

Raises $10M to close first tranche of $25M Financing

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals Inc. announced today that it has closed the first tranche of its $25 million Series B financing to support the advancement of several novel and potent antibiotic drug candidates. This Series B Financing and first tranche of $10 million was funded by existing investors – Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.

Seventh Sense Biosystems, Inc.

Seventh Sense Biosystems Receives Grand Challenges Explorations Grant for Innovative Global Health Research from Gates Foundation

Seventh Sense Biosystems Receives Grand Challenges Explorations Grant for Innovative Global Health Research from Gates Foundation

October 21, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seventh Sense Biosystems announced today that it has received a Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Dr. Howard Bernstein, titled “On-skin and Intra-dermal Malaria Diagnostics with Unprecedented Simplicity of Use Based on Bio-Responsive Particles and Interstitial Fluid Analysis.”

Selecta Biosciences, Inc.

Selecta Co-Founder Named 2009 Mass High Tech All Star

Selecta Co-Founder Named 2009 Mass High Tech All Star

October 29, 2009

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a biopharmaceutical company focused on discovering and developing the first generation of nanoparticle-based vaccines and immunomodulatory drugs for the treatment and prevention of human diseases, announced today that Omid Farokhzad, M.D., co-founder and Vice Chair, has been named as a 2009 Mass High Tech All Star for his contributions to the life sciences industry.